NewAmsterdam Pharma (NAMS) Free Cash Flow (2023 - 2026)

NewAmsterdam Pharma has disclosed Free Cash Flow across 4 years of filings, most recently posting -$30.6 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$30.6 million, up 16.01% year-over-year; the trailing twelve-month figure through Mar 2026 was -$142.2 million (down 1.03% YoY), and the FY2025 annual result was -$148.0 million, up 7.04% from the prior year.
• Free Cash Flow came in at -$30.6 million for Q1 2026 at NewAmsterdam Pharma, up from -$41.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$12.6 million in Q3 2024 to a low of -$55.0 million in Q1 2024.
• The 4-year median for Free Cash Flow is -$37.0 million (2024), against an average of -$37.5 million.
• Across the five-year window, Free Cash Flow jumped 73.23% in 2024 and sank 160.88% in 2025, its largest moves.
• NewAmsterdam Pharma's Free Cash Flow stood at -$33.1 million in 2023, then decreased by 13.32% to -$37.5 million in 2024, then fell by 9.31% to -$41.0 million in 2025, then rose by 25.22% to -$30.6 million in 2026.
• The last three Free Cash Flow figures came in at -$30.6 million (Q1 2026), -$41.0 million (Q4 2025), and -$32.8 million (Q3 2025), per Business Quant data.